4:00 AM
 | 
Jul 17, 2018
 |  BC Extra  |  Financial News

HotSpot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural forms of allosteric regulation, which could open up targets that are not druggable via traditional active site-directed approaches.

While other companies...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >